Franklin FTSE South Korea ETF vs Cassava Sciences Inc — how do they compare? Franklin FTSE South Korea ETF trades at $58.12 (market cap $1.88B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Franklin FTSE South Korea ETF is far larger — about 47.7× Cassava Sciences Inc's market cap, and Franklin FTSE South Korea ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Cassava Sciences Inc for 37 Days on average.
| FLKR | FLNA | |
|---|---|---|
Market Cap | $1.88B | $39.40M |
Volume | 709,775 | 759,018 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $4.64 |
52-Week Low | $27.09 | $0.68 |
Typical Hold Time | 15 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →